

## Disclosures

### Personal Commercial (0)

No disclosures on record

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (3)

Trial Name	Trial Sponsor	Trial Funding Source
Efficacy, safety, and tolerability of AZD9977 and dapagliflozin in patients with heart failure and chronic kidney disease	AstraZeneca Pharmaceuticals	
EMPOWER	Cardiac Dimensions	
Effect of Semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity related heart failure with preserved ejection fraction, and type 2 diabetes	Novo Nordisk Inc.	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2023	LVAD outcome	Defendant	Hospital system was being sued over the death of an LVAD patient by surviving family claiming inadequate care.	Significant (>= \$5,000)

*† Commercial Funding Source | ‡ Trial Name*

## Agreement

### Certified Education Attestation | Signed on 8/8/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement | Signed on 8/8/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo | Signed on 8/8/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement | Signed on 8/8/2025

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.